Call SC1-BHC-17-2020 for prevention and/or early diagnosis of cancer now open!
Prevention, early diagnosis of cancer: call SC1-BHC-17-2020
What we can do, as an SME partner:
For the call SC1-BHC-17-2020, we can bring our expertise in microfluidic instrumentation and flow management to help you develop a lab-on-a-chip platform to detect biomarkers involved in cancer. Specifically, we can:
- Develop a microfluidic setup to inject patient samples into your lab-on-a-chip and allow quick detection of specific cancer biomarkers on site without the need for a proper lab
- Optimize the flow inside your lab on a chip
- Propose a user-friendly and affordable platform for cancer diagnosis, adapted to be used by non-trained medical staff
What labs-on-chip can do for early cancer diagnosis?
The use of microfluidics as a tool for cancer prevention and diagnosis would address the following expected impacts of the call SC1-BHC-17:
- Improve tailored and affordable prevention and/or early diagnosis
⇒ Microfluidic labs-on-chip are a very powerful tool for biomarker detection and, therefore, cancer diagnosis. They can be easily performed on-site, for example, in doctors’ offices, allowing early detection, even in low—and middle-income countries.
- Inform health service providers, policy, and decision-makers on effectively scaling up cancer interventions at local, regional, and national levels, including affordability for users and health providers.
⇒ With a lab-on-a-chip, cancer diagnosis can be performed in a compact device in only a few minutes: it becomes easily accessible, stays affordable since the laboratory costs do not exist, and can be implemented on a large scale.
- Reduce health inequalities and inequities, including due consideration of socio-economic, gender, and age issues where relevant, in the prevention and/or early diagnosis of cancer at both local and global levels
⇒ With lab-on-chip, there is no need to send a sample to a laboratory for long and costly analysis: obtaining a result in a few minutes on-site is possible. This technology can thus be accessible in any country, reducing the inequalities caused by poor access to medical facilities.
The MIC as SME partner
The MIC already brought its microfluidics expertise into many research projects:
H2020-NMBP-TR-IND-2020
Microfluidic platform to study the interaction of cancer cells with lymphatic tissue
H2020-LC-GD-2020-3
Toxicology assessment of pharmaceutical products on a placenta-on-chip model
